May-18 -
Melanoma Group
EORTC1325 – Adjuvant immunotherapy with anti-PD-1 monoclonal antibody Pembrolizumab (MK-3475) versus placebo after complete resection of high-risk Stage III melanoma.
A randomized, double- blind Phase 3 trial of the EORTC Melanoma Group.
EORTC found that 1-year of therapy with immunotherapy treatment (pembrolizumab) after surgery, significantly prolongs time to disease recurrence or death, in patients with high-risk stage III resected melanoma. Based on these results, pembrolizumab treatment was approved by the EMA and FDA.
